While researchers are grateful they can offer patients one of the two approved stabilizers, better therapeutics are still ...
Treatment modalities include liver transplantation for transthyretin-related (ATTR) amyloidosis, elimination of inflammation in amyloid A (AA) amyloidosis and intensive chemotherapy in ...
A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...
AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the space of a couple of months.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hereditary ATTR (hATTR) Amyloidosis Pipeline Report to explore emerging therapies, key Hereditary ATTR (hATTR ...
Various forms of hereditary amyloidosis have been described: transthyretin (ATTR), apolipoprotein (AApo) AI, AApoAII, gelsolin, fibrinogen Aa, cystatin C and lysozyme amyloidosis. Hereditary ...
Nearly 3 months after the FDA green-lit the TTR stabilizer, it joins tafamidis as the second therapy in Europe for the ...
misfolded versions of the protein form dangerous clumps in the heart and along nerves-triggering a progressive and fatal disease known as transthyretin amyloidosis (ATTR). Up to a quarter of all ...
Alnylam has been a pioneer in hereditary ATTR amyloidosis, getting approval in 2018 for the first drug to treat the rare disease, and has now launched a digital companion to help patients track ...
As Alnylam Pharmaceuticals approaches its highly anticipated March 23 FDA decision date for a potential expansion of Amvuttra to treat patients in an increasingly competitive indication—transthyret | ...
under the brand name BEYONTTRAâ„¢, for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback